Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

886P - Circulating tumor DNA kinetics in recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) patients

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Immunotherapy;  Cancer Biology;  Translational Research;  Head and Neck Cancers

Presenters

Kirsty Taylor

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

K. Taylor1, J. Zou2, J. Burgener2, E. Zhao3, D. Torti4, M. Oliva1, A. Spreafico1, A.R. Hansen1, R. Jang1, S.S. McDade5, V.M. Coyle5, M. Lawler5, E. Elimova1, S.V. Bratman3, L.L. Siu1

Author affiliations

  • 1 Division Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, University Health Network, M5G 1Z5 - Toronto/CA
  • 2 Princess Margaret Cancer Centre, University Health Network, M5G 2C1 - Toronto/CA
  • 3 Department Of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, M5G 1Z5 - Toronto/CA
  • 4 Translational Genomics Laboratory, Ontario Institute for Cancer Research, M5M5G 0A3G 1Z5 - Toronto/CA
  • 5 Patrick G. Johnston Centre For Cancer Research, Queens University Belfast, BT9 7AE - Belfast/GB
More

Abstract 886P

Background

Immuno-oncology agents (IO) have become a standard-of-care in the treatment of R/M HNSCC, however only a subset of patients (pts) benefit. Liquid biopsy offers access to circulating tumor DNA (ctDNA); currently data on ctDNA kinetics under treatment selection pressure is limited.

Methods

R/M HNSCC pts treated with either platinum-based chemotherapy (CT) or IO, anti-PD1/L1 (+/- second IO) underwent serial ctDNA collection pre-cycles 1/2/3 and upon disease progression, timepoints (T) 1-4 (NCT03712566). Error-corrected sequencing using a SCC-optimised panel was applied at each available T. After filtering out clonal hematopoiesis-associated mutations, mean variant allele frequency (VAF) was calculated per T. Median ctDNA abundance determined ctDNA groupings and changes were correlated with progression free survival (PFS) and overall survival (OS).

Results

Of the 36 eligible pts (received >=1 cycle) 27 received IO and 9 CT. Median age was 64 (20-82), 67% were male, 72% prior smokers and 92% ECOG PS 1. Median PFS and OS were 2.3 mo (95% CI 0.7-11.2) and 6.9 mo (95% CI 1.9-28) respectively. OS was significantly better in IO treated pts, 6.1 vs 3.9 mo (p = 0.01). Twenty-eight pts (21 IO) had somatic mutations detected at T1. The most frequent TP53 (24%), CDKN2A (16%), FRG1B (14%) and KMT2D (11%). ctDNA abundance at T1 correlated with PFS/OS in both univariate (p = 0.02, p = 0.02) and multivariate cox models (HR 3.22 (1.11-9.38) p = 0.03, HR 3.64 (1.23-10.73) p = 0.02), adjusted for age, gender, treatment, smoking and HPV. Persistence in VAF at T2 correlated significantly with PFS (HR 3.36 (1.50-7.54) p <0.01) and OS (HR 4.62 (1.93-11.06) p <0.01) respectively. Decrease in Δ VAF (T1-2) identified pts with longer OS, despite early radiological progression (Table). Table: 886P

N=27 ΔVAF Decrease T1-T2 ΔVAF Increase T1-2 Median OS (mOS) HR (95% CI; p-value)
CR/PR/SD>=4cycles (A) n=4 [4 IO] (mOS = 20.1mo) (B) n=3 [3 IO] (mOS = 14.4mo) HR [A vs B] = 1.32 95% CI = 0.22-7.69 p = 0.77
PD/SD<4cycles (C) n=10 [8 IO] (mOS = 4.8mo) (D) n=10 [6 IO] (mOS = 3.3mo) HR [C vs D] = 0.34 95% CI = 0.13-0.90 p = 0.03

Conclusions

Low ctDNA abundance at baseline and non-persistence on treatment correlated with improved PFS and OS. Early changes in ctDNA after first treatment may help predict pt outcome beyond RECIST 1.1.

Clinical trial identification

NCT03712566.

Editorial acknowledgement

Legal entity responsible for the study

University Health Network.

Funding

BMO Chair in Precision Cancer Genomics, Ontario Institute for Cancer Research.

Disclosure

M. Oliva: Financial Interests, Personal, Other, Podcast: Merck; Financial Interests, Personal, Invited Speaker, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: MSD. A. Spreafico: Financial Interests, Personal and Institutional, Sponsor/Funding, Consulting: Merck; Financial Interests, Personal and Institutional, Sponsor/Funding, Consulting: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Oncorus; Financial Interests, Personal and Institutional, Sponsor/Funding, Consulting: Janssen/Johnson & Johnson; Financial Interests, Institutional, Sponsor/Funding: Novartis; Financial Interests, Institutional, Sponsor/Funding: Symphogen; Financial Interests, Institutional, Sponsor/Funding: AstraZeneca/Medimmune; Financial Interests, Institutional, Sponsor/Funding: Bayer; Financial Interests, Institutional, Sponsor/Funding: Surface Oncology; Financial Interests, Institutional, Sponsor/Funding: Northern Biologics; Financial Interests, Institutional, Sponsor/Funding: Roche; Financial Interests, Institutional, Sponsor/Funding: Regeneron; Financial Interests, Institutional, Sponsor/Funding: Alkermes; Financial Interests, Institutional, Sponsor/Funding: Array Biopharma/Pfizer; Financial Interests, Institutional, Sponsor/Funding: GSK; Financial Interests, Institutional, Sponsor/Funding: Treadwell. A.R. Hansen: Financial Interests, Personal and Institutional, Sponsor/Funding, Consulting: Merck; Financial Interests, Personal and Institutional, Sponsor/Funding, Consulting: GSK; Financial Interests, Personal and Institutional, Sponsor/Funding, Consulting: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Institutional, Sponsor/Funding: Karyopharm Therapeutics; Financial Interests, Institutional, Sponsor/Funding: Boehringer Ingelheim; Financial Interests, Institutional, Sponsor/Funding: Roche/Genentech; Financial Interests, Institutional, Sponsor/Funding: Janssen; Financial Interests, Institutional, Sponsor/Funding: AZ/Medimmune; Financial Interests, Institutional, Sponsor/Funding: Astellas Pharma; Financial Interests, Institutional, Sponsor/Funding: Macrogenics. R. Jang: Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal and Institutional, Sponsor/Funding, Advisory Role: Novartis; Financial Interests, Institutional, Sponsor/Funding: AstraZeneca; Financial Interests, Institutional, Sponsor/Funding: Merck; Financial Interests, Institutional, Sponsor/Funding: Lilly; Financial Interests, Institutional, Sponsor/Funding: Boston Biomedical ; Financial Interests, Institutional, Sponsor/Funding: Bristol Myers Squibb. V.M. Coyle: Financial Interests, Personal, Advisory Role: Servier; Financial Interests, Institutional, Sponsor/Funding: Bayer; Financial Interests, Institutional, Sponsor/Funding: CellCentric; Financial Interests, Institutional, Sponsor/Funding: Astex Pharmaceuticals ; Financial Interests, Personal, Other, Spouse Honoraria: Gilead Sciences. M. Lawler: Financial Interests, Personal and Institutional, Research Grant, Education grant, Honoraria: Pfizer; Financial Interests, Personal, Invited Speaker, Honoraria: EMD; Financial Interests, Personal, Invited Speaker, Honoraria: Roche; Financial Interests, Personal, Invited Speaker, Honoraria: Carnall Farrar. E. Elimova: Financial Interests, Institutional, Advisory Board, Research Grants: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Board, Research Grants: Zymeworks; Financial Interests, Institutional, Advisory Role: Adaptimmune; Other, Personal, Other, Spouse employee: Merck Vaccines. S.V. Bratman: Financial Interests, Personal, Ownership Interest, Co-founder, patents: DNAMx ; Financial Interests, Institutional, Funding: Nektar Therapeutics ; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Royalties, Patent: Roche. L.L. Siu: Financial Interests, Personal, Advisory Board: Arvinas; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: GeneSeeq; Financial Interests, Personal, Advisory Board: Janpix; Financial Interests, Personal, Advisory Board: Loxo; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Morphosys; Financial Interests, Personal, Advisory Board: Navire; Financial Interests, Personal, Advisory Board: Oncorus; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Relay Therapeutics; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Rubius; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: Symphogen; Financial Interests, Personal, Advisory Board: Tessa; Financial Interests, Personal, Advisory Board: Voronoi; Financial Interests, Personal, Other, Spouse is co-founder: Treadwell Therapeutics; Financial Interests, Personal, Stocks/Shares, Spouse has stock ownership: Agios; Financial Interests, Institutional, Principal Investigator: Amgen; Financial Interests, Institutional, Principal Investigator: Astellas; Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Institutional, Principal Investigator: Avid; Financial Interests, Institutional, Principal Investigator: Bayer; Financial Interests, Institutional, Principal Investigator: Boerhinger-Ingelheim; Financial Interests, Institutional, Principal Investigator: Bristol Myers Squibb; Financial Interests, Institutional, Principal Investigator: GSK; Financial Interests, Institutional, Principal Investigator: Intensity Therapeutics; Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Institutional, Principal Investigator: Mirati; Financial Interests, Institutional, Principal Investigator: Novartis; Financial Interests, Institutional, Principal Investigator: Pfizer; Financial Interests, Institutional, Principal Investigator: Roche/Genentech ; Financial Interests, Institutional, Principal Investigator: Shattucks; Financial Interests, Institutional, Principal Investigator: Symphogen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.